MX2023003652A - Forma cristalina de tegavivint, metodo de preparacion y uso de la misma. - Google Patents

Forma cristalina de tegavivint, metodo de preparacion y uso de la misma.

Info

Publication number
MX2023003652A
MX2023003652A MX2023003652A MX2023003652A MX2023003652A MX 2023003652 A MX2023003652 A MX 2023003652A MX 2023003652 A MX2023003652 A MX 2023003652A MX 2023003652 A MX2023003652 A MX 2023003652A MX 2023003652 A MX2023003652 A MX 2023003652A
Authority
MX
Mexico
Prior art keywords
crystalline form
tegavivint
preparation
crystalline
anthracen
Prior art date
Application number
MX2023003652A
Other languages
English (en)
Inventor
Drazen Ostovic
Gowri Sukumar
Original Assignee
Iterion Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Iterion Therapeutics Inc filed Critical Iterion Therapeutics Inc
Publication of MX2023003652A publication Critical patent/MX2023003652A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención se refiere a formas cristalinas de (9E,10E)-2,7-bis((3,5- dimetilpiperidin-1-il)sulfonil)antraceno-9, 10-diona dioxima, composiciones farmacéuticas que comprenden la forma cristalina, procesos para preparar la forma cristalina y los métodos de uso de la misma.
MX2023003652A 2020-09-29 2021-09-29 Forma cristalina de tegavivint, metodo de preparacion y uso de la misma. MX2023003652A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17/037,287 US11136307B1 (en) 2020-09-29 2020-09-29 Crystalline form of tegavivint, method of preparation, and use thereof
PCT/US2021/052610 WO2022072470A1 (en) 2020-09-29 2021-09-29 Crystalline form of tegavivint, method of preparation, and use thereof

Publications (1)

Publication Number Publication Date
MX2023003652A true MX2023003652A (es) 2023-06-01

Family

ID=77923652

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023003652A MX2023003652A (es) 2020-09-29 2021-09-29 Forma cristalina de tegavivint, metodo de preparacion y uso de la misma.

Country Status (10)

Country Link
US (2) US11136307B1 (es)
EP (1) EP4222148A1 (es)
JP (1) JP2023543055A (es)
KR (1) KR20230145030A (es)
CN (1) CN116323586A (es)
BR (1) BR112023005832A2 (es)
CA (1) CA3193404A1 (es)
IL (1) IL301748A (es)
MX (1) MX2023003652A (es)
WO (1) WO2022072470A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11136307B1 (en) * 2020-09-29 2021-10-05 Iterion Therapeutics, Inc. Crystalline form of tegavivint, method of preparation, and use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101486026B1 (ko) * 2007-05-10 2015-01-22 도그우드 파마슈티컬스, 아이엔씨. 플루오렌, 안트라센, 잔텐, 디벤조수베론 및 아크리딘의 유도체 및 이의 용도
EA022290B1 (ru) * 2008-11-21 2015-12-30 Форест Лэборетериз Холдингз Лимитед Антрахинондиоксимы и их применение
US9963475B2 (en) * 2015-07-28 2018-05-08 Beta Cat Pharmaceuticals, Inc. Anthracene-9, 10-dione dioxime compound prodrugs and their uses
JP7159302B2 (ja) * 2017-06-02 2022-10-24 イテリオン・セラピューティクス・インコーポレイテッド 線維性疾患の治療のための方法
WO2019099836A1 (en) * 2017-11-16 2019-05-23 Northwestern University Inhaled formulation of a molecular inhibitor of wnt/beta-catenin signaling for treating interstitial lung diseases
CN118105343A (zh) * 2018-06-01 2024-05-31 伊特里恩治疗有限公司 特加维因和相关化合物的制剂
US11136307B1 (en) * 2020-09-29 2021-10-05 Iterion Therapeutics, Inc. Crystalline form of tegavivint, method of preparation, and use thereof

Also Published As

Publication number Publication date
EP4222148A1 (en) 2023-08-09
KR20230145030A (ko) 2023-10-17
US20220098173A1 (en) 2022-03-31
BR112023005832A2 (pt) 2023-05-02
CA3193404A1 (en) 2022-04-07
WO2022072470A1 (en) 2022-04-07
CN116323586A (zh) 2023-06-23
US11136307B1 (en) 2021-10-05
IL301748A (en) 2023-05-01
JP2023543055A (ja) 2023-10-12

Similar Documents

Publication Publication Date Title
EA202090917A1 (ru) Получение псилоцибина, различных полиморфных форм, промежуточных соединений, составов и их применение
MX2021002978A (es) Lactamas biciclicas y metodos de uso de las mismas.
TN2018000410A1 (en) New piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
MX2022015106A (es) Proceso para preparar tapinarof.
MY182677A (en) 2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof
WO2019165043A3 (en) Indane-amines as pd-l1 antagonists
MX2017009405A (es) Compuestos de tipo ergolina y usos de estos.
UY27410A1 (es) Formas novedosas crudas cristalinas
CL2011001405A1 (es) Procedimiento para la preparacion de n-[2-(7-metoxi-1-naftil)etil]acetamida, agometalina.
MX2023003652A (es) Forma cristalina de tegavivint, metodo de preparacion y uso de la misma.
WO2015114395A9 (en) Process for the preparation of vortioxetine salts
WO2019078968A3 (en) Cyclic compounds as immunomodulating agents
MX2021001827A (es) Composiciones de trombina liquida estable.
BR112021020964A2 (pt) Inibidor seletivo de quinase jak1
MX2020007562A (es) Nuevas antranilamidas, su uso como insecticida y procesos para su preparacion.
MX2022012239A (es) Compuestos de amida y usos de los mismos.
PH12020550925A1 (en) Pyrazolopyridine-diamides, their use as insecticide and processes for preparing the same.
CY1126077T1 (el) Φαρμακοτεχνικη μορφη αφαμπικινης, μεθοδος για παρασκευη της ιδιας
MX2020004981A (es) Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3.
JOP20220041A1 (ar) عملية صناعية لتحضير إستيرول عالي النقاء
BR112023024953A2 (pt) Processo para fabricação de derivados epóxidos de farneseno e uso dos mesmos em síntese adicional
WO2023122212A3 (en) Substituted phenyl ethynyl pyridine carboxamides as potent inhibitors of sars virus
BR112022012331A2 (pt) Processos de preparação de (e)-1,1,1,4,5,5,5-heptafluoro-4-(trifluorometil)pent-2-eno e composições
MX2017009406A (es) Compuestos de tipo isoergolina y usos de estos.
CU20200091A7 (es) Producto inmunógeno que comprende il-4 y/o il-13